Caris Life Sciences (NASDAQ:CAI) Shares Up 7.5% - Here's What Happened

Key Points

• Shares of Caris Life Sciences were up 7.5% intraday to $19.405 on Monday, but trading was very thin (~128,590 shares, about a 95% decline versus the ~2.5M average).
• The company reported a strong quarter, beating estimates with Q4 EPS of $0.28 versus $0.01 expected and revenue of $292.9M (up 125.4% year‑over‑year).
• Analyst views are mixed: the MarketBeat consensus is "Hold" with an average target of $28.86, though several firms have issued higher targets or buy ratings while others remain cautious.

Shares of Caris Life Sciences, Inc. (NASDAQ:CAI - Get Free Report) were up 7.5% during mid-day trading on Monday . The stock traded as high as $19.44 and last traded at $19.4050. Approximately 128,590 shares changed hands during mid-day trading, a decline of 95% from the average daily volume of 2,500,821 shares. The stock had previously closed at $18.05.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on CAI shares. Robert W. Baird boosted their price target on shares of Caris Life Sciences from $26.00 to $28.00 and gave the stock an "outperform" rating in a research report on Friday, February 27th. Weiss Ratings reissued a "sell (d)" rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Jefferies Financial Group began coverage on shares of Caris Life Sciences in a report on Monday. They issued a "buy" rating and a $28.00 price target on the stock. Canaccord Genuity Group cut their price target on shares of Caris Life Sciences from $30.00 to $22.00 and set a "hold" rating on the stock in a report on Friday, March 13th. Finally, Evercore set a $38.00 price target on shares of Caris Life Sciences in a report on Monday, January 5th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $28.86.

Caris Life Sciences Stock Up 7.1%

The company has a debt-to-equity ratio of 0.66, a quick ratio of 7.35 and a current ratio of 7.85. The business's 50 day simple moving average is $19.55. The firm has a market cap of $5.47 billion and a PE ratio of -107.50.

Caris Life Sciences (NASDAQ:CAI - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.27. The business had revenue of $292.89 million for the quarter, compared to the consensus estimate of $281.00 million. During the same quarter in the previous year, the firm earned ($1.73) EPS. The firm's revenue for the quarter was up 125.4% on a year-over-year basis.

Institutional Trading of Caris Life Sciences

Several institutional investors have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. increased its stake in Caris Life Sciences by 14.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,205,959 shares of the company's stock valued at $248,377,000 after purchasing an additional 1,180,200 shares during the last quarter. Braidwell LP grew its position in shares of Caris Life Sciences by 6.8% during the fourth quarter. Braidwell LP now owns 7,816,142 shares of the company's stock worth $210,880,000 after acquiring an additional 500,000 shares during the last quarter. PointState Capital LP grew its position in shares of Caris Life Sciences by 73.0% during the fourth quarter. PointState Capital LP now owns 6,718,707 shares of the company's stock worth $181,271,000 after acquiring an additional 2,834,986 shares during the last quarter. Orbimed Advisors LLC grew its position in shares of Caris Life Sciences by 2.7% during the fourth quarter. Orbimed Advisors LLC now owns 3,116,011 shares of the company's stock worth $84,070,000 after acquiring an additional 81,153 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Caris Life Sciences by 185.0% in the 4th quarter. JPMorgan Chase & Co. now owns 2,445,281 shares of the company's stock valued at $65,974,000 after buying an additional 1,587,176 shares in the last quarter.

About Caris Life Sciences

Caris Life Sciences NASDAQ: CAI is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.